Thyroid  ||| S:0 E:8 ||| JJ
cysts  ||| S:8 E:14 ||| JJ
treatment  ||| S:14 E:24 ||| NN
with  ||| S:24 E:29 ||| IN
the  ||| S:29 E:33 ||| DT
sclerosing  ||| S:33 E:44 ||| JJ
agent  ||| S:44 E:50 ||| NN
Atossiclerol ||| S:50 E:62 ||| NNP
.  ||| S:62 E:64 ||| .
Long-term  ||| S:64 E:74 ||| JJ
( ||| S:74 E:75 ||| -LRB-
5  ||| S:75 E:77 ||| CD
to  ||| S:77 E:80 ||| TO
15  ||| S:80 E:83 ||| CD
years ||| S:83 E:88 ||| NNS
)  ||| S:88 E:90 ||| -RRB-
follow-up  ||| S:90 E:100 ||| :
The  ||| S:100 E:104 ||| DT
aim  ||| S:104 E:108 ||| NN
of  ||| S:108 E:111 ||| IN
this  ||| S:111 E:116 ||| DT
study  ||| S:116 E:122 ||| NN
was  ||| S:122 E:126 ||| VBD
to  ||| S:126 E:129 ||| TO
evaluate  ||| S:129 E:138 ||| VB
the  ||| S:138 E:142 ||| DT
long-term  ||| S:142 E:152 ||| JJ
efficacy  ||| S:152 E:161 ||| NN
of  ||| S:161 E:164 ||| IN
the  ||| S:164 E:168 ||| DT
sclerosing  ||| S:168 E:179 ||| JJ
agent  ||| S:179 E:185 ||| NN
Atossisclerol  ||| S:185 E:199 ||| NNS
in  ||| S:199 E:202 ||| IN
the  ||| S:202 E:206 ||| DT
treatment  ||| S:206 E:216 ||| NN
of  ||| S:216 E:219 ||| IN
benign ||| S:219 E:225 ||| JJ
,  ||| S:225 E:227 ||| ,
ecolucent ||| S:227 E:236 ||| NN
,  ||| S:236 E:238 ||| ,
thyroid  ||| S:238 E:246 ||| JJ
cysts ||| S:246 E:251 ||| NN
.  ||| S:251 E:253 ||| .
Two  ||| S:253 E:257 ||| CD
groups  ||| S:257 E:264 ||| NNS
of  ||| S:264 E:267 ||| IN
cysts ||| S:267 E:272 ||| NN
,  ||| S:272 E:274 ||| ,
one  ||| S:274 E:278 ||| CD
between  ||| S:278 E:286 ||| IN
1  ||| S:286 E:288 ||| CD
and  ||| S:288 E:292 ||| CC
3  ||| S:292 E:294 ||| CD
cm  ||| S:294 E:297 ||| NNS
and  ||| S:297 E:301 ||| CC
a  ||| S:301 E:303 ||| DT
group  ||| S:303 E:309 ||| NN
smaller  ||| S:309 E:317 ||| JJR
than  ||| S:317 E:322 ||| IN
0.99  ||| S:322 E:327 ||| CD
mm  ||| S:327 E:330 ||| NN
in  ||| S:330 E:333 ||| IN
maximum  ||| S:333 E:341 ||| JJ
diameter  ||| S:341 E:350 ||| NNS
( ||| S:350 E:351 ||| -LRB-
range  ||| S:351 E:357 ||| NN
0.6-0.99 ||| S:357 E:365 ||| CD
)  ||| S:365 E:367 ||| -RRB-
were  ||| S:367 E:372 ||| VBD
considered  ||| S:372 E:383 ||| VBN
in  ||| S:383 E:386 ||| IN
the  ||| S:386 E:390 ||| DT
inclusion  ||| S:390 E:400 ||| NN
plan ||| S:400 E:404 ||| NN
.  ||| S:404 E:406 ||| .
The  ||| S:406 E:410 ||| DT
localization  ||| S:410 E:423 ||| NN
of  ||| S:423 E:426 ||| IN
the  ||| S:426 E:430 ||| DT
cysts  ||| S:430 E:436 ||| NN
was  ||| S:436 E:440 ||| VBD
at  ||| S:440 E:443 ||| IN
lobar  ||| S:443 E:449 ||| JJ
level ||| S:449 E:454 ||| NN
.  ||| S:454 E:456 ||| .
A  ||| S:456 E:458 ||| DT
limited  ||| S:458 E:466 ||| JJ
quantity  ||| S:466 E:475 ||| NN
of  ||| S:475 E:478 ||| IN
Atossisclerol  ||| S:478 E:492 ||| NNP
( ||| S:492 E:493 ||| -LRB-
0.5  ||| S:493 E:497 ||| CD
to  ||| S:497 E:500 ||| TO
2 ||| S:500 E:501 ||| CD
% ||| S:501 E:502 ||| NN
)  ||| S:502 E:504 ||| -RRB-
was  ||| S:504 E:508 ||| VBD
injected ||| S:508 E:516 ||| VBN
.  ||| S:516 E:518 ||| .
No  ||| S:518 E:521 ||| DT
side  ||| S:521 E:526 ||| NN
effects  ||| S:526 E:534 ||| NNS
were  ||| S:534 E:539 ||| VBD
noted ||| S:539 E:544 ||| VBN
.  ||| S:544 E:546 ||| .
After  ||| S:546 E:552 ||| IN
5  ||| S:552 E:554 ||| CD
years  ||| S:554 E:560 ||| NNS
in  ||| S:560 E:563 ||| IN
the  ||| S:563 E:567 ||| DT
group  ||| S:567 E:573 ||| NN
treated  ||| S:573 E:581 ||| VBN
with  ||| S:581 E:586 ||| IN
the  ||| S:586 E:590 ||| DT
sclerosing  ||| S:590 E:601 ||| JJ
agent  ||| S:601 E:607 ||| NN
93 ||| S:607 E:609 ||| CD
%  ||| S:609 E:611 ||| NN
of  ||| S:611 E:614 ||| IN
the  ||| S:614 E:618 ||| DT
cysts  ||| S:618 E:624 ||| NN
were  ||| S:624 E:629 ||| VBD
completely  ||| S:629 E:640 ||| RB
disappeared  ||| S:640 E:652 ||| VBD
( ||| S:652 E:653 ||| -LRB-
vs  ||| S:653 E:656 ||| CD
60 ||| S:656 E:658 ||| CD
%  ||| S:658 E:660 ||| NN
in  ||| S:660 E:663 ||| IN
controls ||| S:663 E:671 ||| NNS
) ||| S:671 E:672 ||| -RRB-
.  ||| S:672 E:674 ||| .
However  ||| S:674 E:682 ||| RB
the  ||| S:682 E:686 ||| DT
initial  ||| S:686 E:694 ||| JJ
target  ||| S:694 E:701 ||| NN
cyst  ||| S:701 E:706 ||| NN
at  ||| S:706 E:709 ||| IN
5  ||| S:709 E:711 ||| CD
and  ||| S:711 E:715 ||| CC
years  ||| S:715 E:721 ||| NNS
was  ||| S:721 E:725 ||| VBD
completely  ||| S:725 E:736 ||| RB
cured  ||| S:736 E:742 ||| VBN
in  ||| S:742 E:745 ||| IN
most  ||| S:745 E:750 ||| JJS
patients  ||| S:750 E:759 ||| NNS
( ||| S:759 E:760 ||| -LRB-
> ||| S:760 E:761 ||| CD
80 ||| S:761 E:763 ||| CD
% ||| S:763 E:764 ||| NN
)  ||| S:764 E:766 ||| -RRB-
treated  ||| S:766 E:774 ||| VBN
with  ||| S:774 E:779 ||| IN
the  ||| S:779 E:783 ||| DT
sclerosing  ||| S:783 E:794 ||| JJ
agent ||| S:794 E:799 ||| NN
;  ||| S:799 E:801 ||| :
at  ||| S:801 E:804 ||| IN
10  ||| S:804 E:807 ||| CD
years  ||| S:807 E:813 ||| NNS
more  ||| S:813 E:818 ||| RBR
than  ||| S:818 E:823 ||| IN
90 ||| S:823 E:825 ||| CD
%  ||| S:825 E:827 ||| NN
of  ||| S:827 E:830 ||| IN
the  ||| S:830 E:834 ||| DT
original ||| S:834 E:842 ||| JJ
,  ||| S:842 E:844 ||| ,
sclerosed  ||| S:844 E:854 ||| JJ
target  ||| S:854 E:861 ||| NN
cysts  ||| S:861 E:867 ||| NNS
were  ||| S:867 E:872 ||| VBD
not  ||| S:872 E:876 ||| RB
visible ||| S:876 E:883 ||| JJ
.  ||| S:883 E:885 ||| .
Another  ||| S:885 E:893 ||| DT
control  ||| S:893 E:901 ||| NN
of  ||| S:901 E:904 ||| IN
most  ||| S:904 E:909 ||| JJS
of  ||| S:909 E:912 ||| IN
these  ||| S:912 E:918 ||| DT
patients  ||| S:918 E:927 ||| NNS
( ||| S:927 E:928 ||| -LRB-
53 ||| S:928 E:930 ||| CD
/ ||| S:930 E:931 ||| CD
68 ||| S:931 E:933 ||| CD
)  ||| S:933 E:935 ||| -RRB-
at  ||| S:935 E:938 ||| IN
15  ||| S:938 E:941 ||| CD
years  ||| S:941 E:947 ||| NNS
indicated  ||| S:947 E:957 ||| VBD
that  ||| S:957 E:962 ||| DT
sclerosis  ||| S:962 E:972 ||| NN
of  ||| S:972 E:975 ||| IN
the  ||| S:975 E:979 ||| DT
cyst  ||| S:979 E:984 ||| NN
is  ||| S:984 E:987 ||| VBZ
safe  ||| S:987 E:992 ||| JJ
and  ||| S:992 E:996 ||| CC
allow  ||| S:996 E:1002 ||| VB
a  ||| S:1002 E:1004 ||| DT
better  ||| S:1004 E:1011 ||| RBR
occlusion ||| S:1011 E:1020 ||| JJ
/ ||| S:1020 E:1021 ||| CD
obliteration  ||| S:1021 E:1034 ||| NNS
( ||| S:1034 E:1035 ||| -LRB-
in  ||| S:1035 E:1038 ||| IN
almost  ||| S:1038 E:1045 ||| RB
all  ||| S:1045 E:1049 ||| DT
patients ||| S:1049 E:1057 ||| NNS
)  ||| S:1057 E:1059 ||| -RRB-
of  ||| S:1059 E:1062 ||| IN
the  ||| S:1062 E:1066 ||| DT
cyst  ||| S:1066 E:1071 ||| NN
in  ||| S:1071 E:1074 ||| IN
comparison  ||| S:1074 E:1085 ||| NN
with  ||| S:1085 E:1090 ||| IN
aspiration  ||| S:1090 E:1101 ||| VBG
only  ||| S:1101 E:1106 ||| RB
( ||| S:1106 E:1107 ||| -LRB-
slow  ||| S:1107 E:1112 ||| JJ
recurrence  ||| S:1112 E:1123 ||| NN
in  ||| S:1123 E:1126 ||| IN
some  ||| S:1126 E:1131 ||| DT
25 ||| S:1131 E:1133 ||| CD
%  ||| S:1133 E:1135 ||| NN
of  ||| S:1135 E:1138 ||| IN
the  ||| S:1138 E:1142 ||| DT
cysts ||| S:1142 E:1147 ||| NN
) ||| S:1147 E:1148 ||| -RRB-
.  ||| S:1148 E:1150 ||| .
The  ||| S:1150 E:1154 ||| DT
sclerosing  ||| S:1154 E:1165 ||| JJ
agent  ||| S:1165 E:1171 ||| NN
can  ||| S:1171 E:1175 ||| MD
be  ||| S:1175 E:1178 ||| VB
re-injected  ||| S:1178 E:1190 ||| JJ
in  ||| S:1190 E:1193 ||| IN
the  ||| S:1193 E:1197 ||| DT
same  ||| S:1197 E:1202 ||| JJ
patients  ||| S:1202 E:1211 ||| NNS
without  ||| S:1211 E:1219 ||| IN
significant  ||| S:1219 E:1231 ||| JJ
reaction  ||| S:1231 E:1240 ||| NN
or  ||| S:1240 E:1243 ||| CC
clinical  ||| S:1243 E:1252 ||| JJ
problems  ||| S:1252 E:1261 ||| NNS
or  ||| S:1261 E:1264 ||| CC
immunological  ||| S:1264 E:1278 ||| JJ
reactions ||| S:1278 E:1287 ||| NNS
.  ||| S:1287 E:1289 ||| .
